Careddu Domenico, Pettenazzo Andrea
Pediatrics, Italian Health Service, Cameri, Italy.
Department of Women's and Children's Health, University Hospital of Padua, Padova, Italy.
Int J Gen Med. 2018 Mar 8;11:91-98. doi: 10.2147/IJGM.S154198. eCollection 2018.
In numerous randomized controlled trials (RCTs) and systematic reviews such as those published by the Cochrane Collaboration, extract EPs 7630 was shown to be effective in acute respiratory tract infections (aRTI) in all investigated age-groups. This narrative review focuses on recently published results from RCTs investigating the clinical efficacy and safety of EPs 7630 in children and adolescents with different manifestations of aRTI, in order to present a broader overview and to provide an update on the state of knowledge regarding the use of EPs 7630 in this age-group.
The Cochrane review on extract for aRTI published by the Cochrane Collaboration was searched for cited RCTs with EPs 7630 in children and adolescents suffering from aRTI. A PubMed and SCOPUS literature search was performed for publications issued before June 13, 2017 (search terms: children, , EPs 7630, respiratory). Reference lists of publications found were searched for relevant citations.
Eight RCTs investigating the application of EPs 7630 in acute bronchitis, acute tonsil-lopharyngitis, and aRTI in the context of chronic preconditions were identified. Results showed a statistically significant improvement of aRTI symptom severity for EPs 7630 as compared to controls. The investigation of EPs 7630 in asthmatic children and adolescents with aRTI demonstrated a significant symptom-alleviating effect and a possibly associated reduction of asthma attacks. In immunocompromised children with acute upper RTI, an alleviating effect of EPs 7630 was shown. All RCTs reviewed reported good safety and tolerability of EPs 7630.
The extract EPs 7630 is effective and safe for those of pediatric age and may be regarded as an alternative option for the management of aRTI.
在众多随机对照试验（RCT）以及诸如Cochrane协作网发表的系统评价中，提取物EPs 7630在所有研究年龄组的急性呼吸道感染（aRTI）中均显示出有效性。本叙述性综述聚焦于近期发表的RCT结果，这些研究调查了EPs 7630在患有不同表现形式aRTI的儿童和青少年中的临床疗效及安全性，以便提供更全面的概述，并更新关于该年龄组使用EPs 7630的知识状况。
检索Cochrane协作网发表的关于aRTI提取物的Cochrane综述，以查找在患有aRTI的儿童和青少年中使用EPs 7630的引用RCT。对2017年6月13日前发表的文献进行PubMed和SCOPUS文献检索（检索词：儿童、EPs 7630、呼吸道）。对所发现出版物的参考文献列表进行相关引用检索。
确定了8项RCT，这些研究调查了EPs 7630在急性支气管炎、急性扁桃体 - 咽炎以及慢性疾病背景下的aRTI中的应用。结果显示，与对照组相比，EPs 7630使aRTI症状严重程度有统计学意义的改善。对患有aRTI的哮喘儿童和青少年中EPs 7630的研究表明，其具有显著的症状缓解作用以及可能相关的哮喘发作减少。在免疫功能低下的急性上呼吸道感染儿童中，显示出EPs 7630的缓解作用。所有纳入综述的RCT均报告EPs 7630具有良好的安全性和耐受性。
提取物EPs 7630对儿童有效且安全，可被视为治疗aRTI的一种替代选择。
